Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19212993 | 0.89 | MEN1 (0.44) | KMT2AMEN1CA14CA12CA7 | |
| SCHEMBL2607007 | 0.88 | MEN1 (0.45) | KMT2AMEN1HDAC6HDAC1HDAC2 | |
| SCHEMBL21335943 | 0.85 | MEN1 (0.48) | KMT2AMEN1CA14CA12KDM5A | |
| SCHEMBL2606995 | 0.84 | MEN1 (0.40) | KMT2AMEN1HDAC6HDAC1HDAC2 | |
| SCHEMBL3661154 | 0.82 | TDP1 (0.46) | KMT2AMEN1CA14CA12CA7 | |
| SCHEMBL9199990 | 0.82 | KMT2A (0.37) | KMT2AMEN1HDAC6HDAC1HDAC2 | |
| SCHEMBL948960 | 0.79 | MEN1 (0.36) | KMT2AMEN1HDAC6HDAC1HDAC2 | |
| SCHEMBL12662980 | 0.79 | KDM5A (0.41) | KMT2AMEN1CA14CA12KDM5A | |
| SCHEMBL16325434 | 0.79 | MEN1 (0.60) | KMT2AMEN1CA14CA12KDM5A | |
| SCHEMBL26157797 | 0.79 | TDP1 (0.54) | KMT2AMEN1CA14CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| EP-3488870-B1 | ANTI-CD70 ANTIBODY DRUG CONJUGATES | AMBRX INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | AMBRX,INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210277056-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10800856-B2 | Prostate-specific membrane antigen antibody drug conjugates | AMBRX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3470413-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | Ambrx, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-9796754-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | KMT2A 2012/4885MEN1 4326/4885HDAC6 902/4885 |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | CD74, CD63, CD47 | KMT2A 2012/4885MEN1 4326/4885HDAC6 902/4885 |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | KMT2A 2012/4885MEN1 4326/4885HDAC6 902/4885 |
| US-10800856-B2 | Prostate-specific membrane antigen antibody drug conjugates | KLK3, PTMS, DDOST | KMT2A 958/4885MEN1 1371/4885HDAC6 1680/4885 |
| US-20210277056-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | DDOST, DAD1, PTMS | KMT2A 2757/4885MEN1 3928/4885HDAC6 1222/4885 |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DAD1, PTMS | KMT2A 2757/4885MEN1 3928/4885HDAC6 1222/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | KMT2A 1890/4885MEN1 3955/4885HDAC6 1106/4885 |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | KLK3, PTMS, DDOST | KMT2A 958/4885MEN1 1371/4885HDAC6 1680/4885 |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | KLK3, PTMS, DDOST | KMT2A 958/4885MEN1 1371/4885HDAC6 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.